News and Blog

News and Blog

Date:
08-02-13

Author:
Empower

Open to all

Open to all

This week has seen a significant step taken on the road to fuller transparency on drug trials. I congratulate AllTrials.net, the Medical Research Council, British Medical Journal and, of course, The Times in highlighting this vital issue.

GlaxoSmithKline’s (GSK) decision to expand on their commitment to publish both negative and positive drug trial data is truly praiseworthy. This is a substantial undertaking, given that all patients’ data will have to anonymised, but it is without question the right direction of travel. Let us hope that more companies follow their example.

As I have outlined on previous occasions, when addressing a problem it is just as important to have a full understanding of what doesn’t work as it is to have an understanding of what does. Opening up clinical trial data will significantly benefit the scientific community as it will stop drug developers from walking down an already trodden path (as in not retesting a drug that has already been tested). This openness of data is by no means an end in itself; it will not create a new drug. However it should speed up the process of development immensely.

What should also be noted is how this decision has come about. It wasn’t through a court case, it wasn’t through scandal and it wasn’t even market driven. It has come about through the pressure exerted through a campaign with modest roots. Ben Goldacre and other initiates have demonstrated that “big pharma” are not the immovable force as often characterised.

It has never been clearer to me that we must maintain the pressure and keep this issue on the agenda of policy makers and industry leaders.

Comments

  • I read Les’s article in the ST today 10.02.13 and was impressed with the clarity of the campaign.

    I run a small Pharmaceutical company in Essex and we have developed two synthetic cannabinoids used in palliative care when existing therapies fail to work. There is supporting data for use of these compounds in ALS. Both are known to MHRA in terms of safety and tolerability and are known neuro protective agents.

    I would welcome further engagement with Empower. 


    Andrew Davies
    Director
    STI Pharmaceuticals Ltd
    Brentwood Essex  

                 

    Andrew Davies 10-02-13 7:46pm

  • There is a Drug undergoing trials that has orphan status It is having significant success with MS and other autoimmune diseases. It is ;Aimspro; I can supply the name of the clinical director if required

    Andrew Philpott 12-02-13 9:16am

Add your comment

Please enter the word you see in the image below:


Categories

Recent Articles

Latest Tweets

Press Enquiries

Please contact James Hargrave at JBP PR or telephone 0203 267 0074 for any press or event related enquiries.